Takeda Pharmaceutical Co Ltd (4502.T)
22 May 2018
LONDON For Christophe Weber, the boss of Japan's Takeda Pharmaceutical , securing a $62 billion deal last week to buy drugmaker Shire at the fifth time of asking was the easy bit.
* Takeda boss to raise bar for pipeline drugs after Shire deal
* Takeda looking to strengthen pipeline by acquiring Shire (Adds executive comment, details)
TOKYO Japan's Takeda Pharmaceutical Co Ltd on Monday forecast a 17 percent fall in operating profit for the year through March 2019 as blood cancer drug Velcade looks set to lose exclusivity in the U.S.
TOKYO, May 14 Japan's Takeda Pharmaceutical Co Ltd reported on Monday a 55.1 percent jump in annual operating profit, buoyed by growing sales of bowel disease drug Entyvio and heartburn and ulcer drug Takecab.
* Loans: JP Morgan leads US$30.85bn bridge for Shire acquisition
LONDON British serviced office provider IWG has attracted takeover approaches from three rival suitors, potentially plunging the $3.1 billion company into a bidding war.
LONDON/TOKYO Takeda Pharmaceutical agreed to buy London-listed Shire for 45.3 billion pounds ($62 billion) on Tuesday, the biggest yet in a wave of deals sweeping the drugs industry. | Video
May 8 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:
LONDON (Reuters Breakingviews) - Takeda Pharmaceutical is swallowing a big dose of risk to buy Shire. The Japanese drugmaker finally struck a deal to take control of its Irish peer, for $62 billion. It can just about make the math work, but requires big spending cuts and a load of debt.